A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73621467" target="_blank" >RIV/61989592:15110/23:73621467 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15640/23:73621467

Výsledek na webu

<a href="https://www.mdpi.com/1467-3045/45/10/521" target="_blank" >https://www.mdpi.com/1467-3045/45/10/521</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cimb45100521" target="_blank" >10.3390/cimb45100521</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

Popis výsledku v původním jazyce

Hepatitis C virus (HCV) infection is a worldwide public health problem. Chronic infection with HCV can lead to liver cirrhosis or cancer. Although some immune-competent individuals can clear the virus, others develop chronic HCV disease due to viral mutations or an impaired immune response. IFNs type I and III and the signal transduction induced by them are essential for a proper antiviral effect. Research on the viral cycle and immune escape mechanisms has formed the basis of therapeutic strategies to achieve a sustained virological response (SVR). The first therapies were based on IFN alpha; then, IFN alpha plus ribavirin (IFN-RBV); and then, pegylated-IFN alpha-RBV (PEGIFN alpha-RIV) to improve cytokine pharmacokinetics. However, the maximum SVR was 60%, and several significant side effects were observed, decreasing patients&apos; treatment adherence. The development of direct-acting antivirals (DAAs) significantly enhanced the SVR (&gt;90%), and the compounds were able to inhibit HCV replication without significant side effects, even in paediatric populations. The management of coinfected HBV-HCV and HCV-HIV patients has also improved based on DAA and PEG-IFN alpha-RBV (HBV-HCV). CD4 cells are crucial for an effective antiviral response. The IFN lambda 3, IL28B, TNF-alpha, IL-10, TLR-3, and TLR-9 gene polymorphisms are involved in viral clearance, therapeutic responses, and hepatic pathologies. Future research should focus on searching for strategies to circumvent resistance-associated substitution (RAS) to DAAs, develop new therapeutic schemes for different medical conditions, including organ transplant, and develop vaccines for long-lasting cellular and humoral responses with cross-protection against different HCV genotypes. The goal is to minimise the probability of HCV infection, HCV chronicity and hepatic carcinoma.

Název v anglickém jazyce

A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

Popis výsledku anglicky

Hepatitis C virus (HCV) infection is a worldwide public health problem. Chronic infection with HCV can lead to liver cirrhosis or cancer. Although some immune-competent individuals can clear the virus, others develop chronic HCV disease due to viral mutations or an impaired immune response. IFNs type I and III and the signal transduction induced by them are essential for a proper antiviral effect. Research on the viral cycle and immune escape mechanisms has formed the basis of therapeutic strategies to achieve a sustained virological response (SVR). The first therapies were based on IFN alpha; then, IFN alpha plus ribavirin (IFN-RBV); and then, pegylated-IFN alpha-RBV (PEGIFN alpha-RIV) to improve cytokine pharmacokinetics. However, the maximum SVR was 60%, and several significant side effects were observed, decreasing patients&apos; treatment adherence. The development of direct-acting antivirals (DAAs) significantly enhanced the SVR (&gt;90%), and the compounds were able to inhibit HCV replication without significant side effects, even in paediatric populations. The management of coinfected HBV-HCV and HCV-HIV patients has also improved based on DAA and PEG-IFN alpha-RBV (HBV-HCV). CD4 cells are crucial for an effective antiviral response. The IFN lambda 3, IL28B, TNF-alpha, IL-10, TLR-3, and TLR-9 gene polymorphisms are involved in viral clearance, therapeutic responses, and hepatic pathologies. Future research should focus on searching for strategies to circumvent resistance-associated substitution (RAS) to DAAs, develop new therapeutic schemes for different medical conditions, including organ transplant, and develop vaccines for long-lasting cellular and humoral responses with cross-protection against different HCV genotypes. The goal is to minimise the probability of HCV infection, HCV chronicity and hepatic carcinoma.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/LX22NPO5103" target="_blank" >LX22NPO5103: Národní institut virologie a bakteriologie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Issues in Molecular Biology

ISSN

1467-3037

e-ISSN

1467-3045

Svazek periodika

45

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

22

Strana od-do

"8255 "- 8276

Kód UT WoS článku

001096530900001

EID výsledku v databázi Scopus

2-s2.0-85175040315